NCT07032077

A Clinical Trial of HRS-7058 Combined Anti-tumor Drugs in Subjects With Solid Tumors

A Phase II Clinical Trial on the Safety, Tolerability, and Efficacy of HRS-7058 Combined Anti-tumor Drugs in Subjects With Solid Tumors

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Shandong Suncadia Medicine Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study aims to evaluate the safety and tolerability of HRS-7058 combined with antitumor drugs in subjects with solid tumors, and to determine the recommended dosage for Phase II. Evaluate the objective response rate of HRS-7058 in combination with anti-tumor drugs in subjects with solid tumors.

Conditions

• Solid Tumors

Interventions

Type	Name	Description
DRUG	HRS-7058	HRS-7058 combined with antitumor drugs.

Timeline

• Start date: 2025-07-09
• Primary completion: 2027-06-01
• Completion: 2027-07-01
• First posted: 2025-06-22
• Last updated: 2026-03-20

Locations

1 site across 1 country: China